Naltrexone attenuates self-injurious behavior in mentally retarded subjects
References (20)
- et al.
Failure of naloxone to reduce self-injurious behavior in two developmentally disabled females
Appl Res Ment Retardat
(1986) - et al.
Effects of naloxone on self-injurious behavior. A case study
Appl Res Ment Retardat
(1983) - et al.
Effects of naloxone in a previously undescribed hypothalamic syndrome
Lancet
(1980) - et al.
Cataleptic effects of dynorphin-(1–13) in rats made tolerant to a mu opiate receptor agonist
Neuropeptides
(1981) - et al.
Behavioral effects and in vivo degradation of intraventricularly administered dynorphin-(1–13) and D-Ala2dynorphin-(1–11) in rats
Life Sci
(1980) - et al.
Naloxone attenuates self-abusive behavior in developmentally disabled clients
Appl Res Ment Retardat
(1983) - et al.
Naltrexone in treatment of self-injurious behavior: a clinical study
Res Develop Disab
(1987) - et al.
Dependence creating properties of lipotropin C-fragment (β-endorphin): Evidence for its internal control of behavior
Life Sci
(1979) Congenital insensitivity and naloxone
Lancet
(1978)- et al.
Endogenous opioids: Biology and function
Ann Rev Neurosc
(1984)
Cited by (65)
Hypothalamic opioid-Melanocortin appetitive balance and addictive craving
2011, Medical HypothesesCitation Excerpt :It is also highly effective in the management of chronic alcoholism especially where its administration is supervised by a significant other [117–121]. It has also been described as having useful activity in a variety of other addictions including cannabis, amphetamine, cocaine, self-mutilation, overeating-obesity and gambling [2,111,116,122–132]. Naltrexone has been described as mildly stimulating the HPA axis in humans [133], an effect opposite to that described for opiate agonists (see above).
Naltrexone as a treatment of self-injurious behavior: A case report
2001, European PsychiatryPlasma adrenocorticotropin responses to opioid blockade with naloxone: Generating a dose-response curve in a single session
2000, Biological PsychiatryCitation Excerpt :Investigations with opioid antagonists have shown that CNS opioids impose tonic inhibition on the hypothalamic–pituitary–gonadal as well as the hypothalamic–pituitary–adrenal axes (Genazzani et al 1995; Inder et al 1995). Such studies have also suggested a role for the CNS opioid system in a number of neuropsychiatric disorders, including alcoholism (Wand et al 1998, 1999); autism (Campbell and Harris 1996); Gilles de la Tourette syndrome (Gillman and Sandyk 1985); obsessive-compulsive disorder (Keuler et al 1996); self-mutilation (Kars et al 1990; Lienemann and Walker 1989); trichotillomania (Carrion 1995); anorexia nervosa (Kaye et al 1987); and mood (Cohen et al 1983a, 1983b; Martin del Campo et al 1992, 1994). Moreover, antagonist studies have suggested that CNS opioids may help modulate learning and memory (Cohen et al 1983; Introini-Collison et al 1995; Izquierdo 1982; McGaugh et al 1986; Olson et al 1995).
Effects of dopamine, NMDA, opiate, and serotonin-related agents on acute methamphetamine-induced self-injurious behavior in mice
2000, Pharmacology Biochemistry and BehaviorDevelopmental Considerations for the Use of Naltrexone in Children and Adolescents
2021, Journal of Pediatric Pharmacology and TherapeuticsTreatment of non-suicidal self-injurious behavior in adolescents
2019, Psychiatric Times